6505--Ropinirole Tablet
Overview
Buyer
Place of Performance
NAICS
PSC
Set Aside
Original Source
Timeline
Qualification Details
Fit reasons
- NAICS alignment with historical contract wins in similar service areas.
- Scope strongly matches core technical capabilities and delivery model.
Risks
- Past performance thresholds may require one additional teaming partner.
- Potential clarification needed on staffing minimums before bid/no-bid.
Next steps
Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.
Quick Summary
The Department of Veterans Affairs (VA), specifically NAC PHARMACEUTICALS (36E797), has issued a solicitation (36E79726R0019) for Ropinirole HCL Tablets. This Firm Fixed Price, Indefinite-Delivery Requirements contract aims to establish national contract prices for distribution through the VA and DoD Pharmaceutical Prime Vendor (PPV) Programs, ensuring product availability and consistent pricing for VA, DoD, Bureau of Prisons (BOP), and Indian Health Service (IHS). Proposals are due April 30, 2026.
Scope of Work
The solicitation requires the provision of various strengths and package sizes of ROPINIROLE HCL tablets. Key aspects include:
- Establishing national contract prices for Ropinirole HCL tablets.
- Ensuring product availability and consistency nationwide.
- Distribution through VA and DoD Pharmaceutical Prime Vendor Programs.
Key Requirements
- Product Specifications: Offerors must submit prices for all 13 line items for the base year and all four option years. Products must meet specific packaging requirements (safety caps for bottles <=400 tablets, compatibility with automated dispensing units, no glass bottles).
- Labeling & Compliance: All pharmaceutical products must include bar code labeling conforming to GS1-128 or HIBCC standards. Compliance with Drug Supply Chain Security Act (DSCSA) requirements, including serialized DSCSA Transaction Information and Transaction Statements using GS1 EPCIS files, is mandatory.
- Identification: Offerors must provide a unique 11-digit National Drug Code (NDC) for each product.
- Manufacturing: Manufacturing facilities must have an acceptable cGMP status on record with the FDA. A Letter of Commitment from the manufacturer is required if the offeror is not the manufacturer.
Contract Details
- Contract Type: Firm Fixed Price, Indefinite-Delivery Requirements contract.
- Duration: Implementation Period plus one (1) year Ordering Period with four (4) one (1) year pre-priced option periods.
- Set-Aside: Unrestricted. Non-small business concerns with contracts over $900,000 must submit an approved subcontracting plan.
- Estimated Quantities: Provided in Attachment C for VA, DoD, BOP, and IHS.
Submission & Evaluation
- Submission Method: Proposals must be submitted via email to Michael.Olszewski@va.gov in Microsoft Word or PDF format, including a scanned PDF of the signed SF-1449. Faxed proposals are not acceptable. Zip files and folders are rejected.
- Proposal Content: Offerors must submit prices for all line items for the base year and all four option years. Proposals failing to price all line items for all years may be rejected. Prices must include a 0.50% Cost Recovery Fee.
- Evaluation: Offers will be evaluated on a Lowest Price Technically Acceptable (LPTA) basis. Technical acceptability includes meeting product descriptions, unique NDC, FDA approval, FDA cGMP compliance, and manufacturing facility clearance.
- Response Due: April 30, 2026, 2:30 PM CT (19:30 UTC).
- Contact: Michael J Olszewski, Contract Specialist, Michael.Olszewski@va.gov.
Additional Notes
Offerors are responsible for confirming receipt of their proposals and must maintain current and accurate records in the System for Award Management (SAM). For covered drugs, offerors must have a Master Agreement (MA) and Pharmaceutical Pricing Agreement (PPA) in place with the VA.